First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): phase 1 results
Authors
Halperin, DMJohnson, ML
Meyer, T
Fojo, AT
Cook, Natalie
Blaszkowsky, LS
Schlechter, BL
Chan, J
Yao, JC
Jemiai, Y
Kriksciukaite, K
Mei, L
Shonukan, T
Alland, L
Wooster, R
Kulke, MH
Affiliation
University of Texas MD Anderson Cancer Center, HoustonIssue Date
2019